ATI RN Pharmacology 2019 Exam 6

Extract:

Question 1 of 5

A nurse recently administered filgrastim intravenously to a client who has cancer and is receiving cytotoxic chemotherapy. For which of the following data, discovered after the medication was administered, should the nurse file an incident report?

A. The client's absolute neutrophil count was 2,500/mm3 before the medication was administered. B. The medication vial sat at room temperature for 2 hr before it was administered. C. The client had chemotherapy 12 hr before the medication was administered. D. The nurse flushed the client's IV line with dextrose 5% in water before and after the medication was administered.

Correct Answer: B

Rationale: The correct answer is B because filgrastim should be stored and administered according to the manufacturer's guidelines, typically at refrigerated temperatures to maintain stability. Allowing the medication vial to sit at room temperature for 2 hours may compromise its efficacy and safety. This deviation from proper storage and handling procedures could potentially lead to adverse effects on the client.

Choices A, C, and D are not appropriate reasons for filing an incident report in this scenario.
Choice A indicates a normal neutrophil count before administration, which is not a direct consequence of the incorrect handling of the medication.
Choice C, the timing of the chemotherapy, is unrelated to the administration of filgrastim.
Choice D, flushing the IV line with dextrose 5% in water, is a standard practice and not a reason for filing an incident report unless there were complications directly related to the flush.

Question 2 of 5

Correct Answer:

Rationale:

Question 3 of 5

Correct Answer:

Rationale:

Question 4 of 5

Correct Answer:

Rationale:

Question 5 of 5

Correct Answer:

Rationale:

ATI RN Pharmacology 2019 Exam 6 | Nurselytic

Nurselytic

ATI RN

ATI RN